Daewoong Pharma (069620) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Daewoong Pharma KRW 244,351, price KRW 106,200, upside +130.1%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Daewoong Pharma for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 91,039 KRW – 194,000 KRW · fair‑value band 168,958 KRW – 319,744 KRW · the 106,200 KRW price screens below the 244,351 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Daewoong Pharma in your weekly email
Every Wednesday you see whether Daewoong Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
Show more
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Stock analysis
Daewoong Pharma (069620) currently trades at 106,200 KRW, while our model-based Fair Value estimate is 244,351 KRW, implying the stock looks roughly 56.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 335,198 KRW per share, and 13 of the 14 models we run sit above the 106,200 KRW price.
Bear case: the Asset-Based group reads lowest at 58,584 KRW, and 1 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: 168,958 KRW (bear) to 319,744 KRW (bull), the price of 106,200 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Daewoong Pharma reported revenue of 1.6T KRW in FY2025 versus 1.2T KRW in FY2021, a compound +8.0%/yr. Reported net income was 196B KRW in FY2025, compounding +67.9%/yr from FY2021.
Key figures
Market cap 1.4T KRW (≈ $997M) · P/S ratio 0.89 · Dividend yield 0.6% · Net margin 12.5% · Return on equity 19.1% · Return on assets (EBIT) 7.2% · Operating margin 5.9% · Revenue (TTM) 1.6T KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 130%, 069620 screens cheaper than that median.
Fair Value models
Bear 168,958 KRWFair Value 244,351 KRWBull 319,744 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.47/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Start year 2020 (pandemic). Over 10 years: +6.5% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+71.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+70.4%
Dividend (yield on the price)0.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 13%
2025 sits 346% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+130% · Top 25%
Profitability
Return on equity (TTM)19% · Top 25%
Return on assets5% · Above median
Net margin (TTM)13% · Above median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth6% · Above median
Dividend yield (TTM)0.6% · Bottom 25%
Balance sheet
Debt / equity0.55× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daewoong Pharma Fair Value". https://www.fairvalue-calculator.com/stock/069620
Frequently asked questions
Is Daewoong Pharma (069620) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 244,351 KRW versus a price of 106,200 KRW, about +130% upside (undervalued).
What is the fair value of 069620?
Our model-based fair value for Daewoong Pharma is 244,351 KRW (as of Sep 23, 2026), built from audited fundamentals. The current price: 106,200 KRW.
What is the quality score of 069620?
Daewoong Pharma has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daewoong Pharma (069620)?
Our model-based price target is the fair value of 244,351 KRW (as of Sep 23, 2026) from 14 valuation models. Cautious scenario 168,958 KRW, optimistic scenario 319,744 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daewoong Pharma stock forecast for 2026?
Our models put fair value at 244,351 KRW, about +130% upside versus a price of 106,200 KRW (undervalued). Cautious scenario 168,958 KRW, optimistic scenario 319,744 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daewoong Pharma (069620)?
Daewoong Pharma reported trailing-twelve-month revenue of about 1.6T KRW (latest available figure, as of Sep 23, 2026).
Does Daewoong Pharma pay a dividend?
Daewoong Pharma currently shows a dividend yield of about 0.56% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Daewoong Pharma (069620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daewoong Pharma it is 244,351 KRW per share (as of Sep 23, 2026), against a price of 106,200 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Daewoong Pharma stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 069620 trades below its calculated fair value: price 106,200 KRW, fair value 244,351 KRW, a gap of about +130% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 069620?
No. The price is what the market pays today (106,200 KRW); the fair value is what the company's own numbers justify (244,351 KRW). For Daewoong Pharma the two are 138,151 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daewoong Pharma worth?
The market values Daewoong Pharma at about 1.4T KRW (market capitalisation, as of Sep 23, 2026). Per share that is 106,200 KRW; our models calculate a fair value of 244,351 KRW per share.
What do the bullish and bearish scenarios say about 069620?
Our models span a range for Daewoong Pharma: cautious scenario 168,958 KRW, base 244,351 KRW, optimistic 319,744 KRW per share (as of Sep 23, 2026, price 106,200 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Daewoong Pharma (069620)?
Balance-sheet figures for Daewoong Pharma (as of Sep 23, 2026): return on equity 19.1%, debt of 0.55 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 069620 from its 52-week high?
Daewoong Pharma trades at 106,200 KRW, about 45% below its 52-week high of 194,000 KRW and at the low of 106,200 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 244,351 KRW is for.
Which stocks are comparable to Daewoong Pharma?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daewoong Pharma stock attractive at the current price?
The data as of Sep 23, 2026: price 106,200 KRW, calculated fair value 244,351 KRW (+130%), Quality Score 48/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 069620 calculated?
We run Daewoong Pharma through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 244,351 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Daewoong Pharma currently trades 130 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daewoong Pharma (069620)?
The closing price on Sep 23, 2026 was 106,200 KRW. Our model-based fair value is 244,351 KRW, about +130% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daewoong Pharma right now?
The price is below even our cautious bear case (168,958 KRW). The market is more pessimistic than our downside scenario. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (168,958 KRW to 319,744 KRW) leaves room in how you read the outcome.
Key figures of Daewoong Pharma
How large is the market capitalisation of Daewoong Pharma (069620)?
The market capitalisation of Daewoong Pharma is 1.4T KRW (≈ $997M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daewoong Pharma (069620)?
The price-to-sales ratio of Daewoong Pharma is 0.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Daewoong Pharma (069620)?
The dividend yield of Daewoong Pharma is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daewoong Pharma (069620)?
The net margin of Daewoong Pharma is 12.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daewoong Pharma (069620)?
The return on equity (ROE) of Daewoong Pharma is 19.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daewoong Pharma (069620)?
On an EBIT basis the return on assets of Daewoong Pharma is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daewoong Pharma (069620)?
The operating margin of Daewoong Pharma is 5.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daewoong Pharma (069620)?
Revenue at Daewoong Pharma is growing +6.0% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daewoong Pharma (069620)?
Earnings per share at Daewoong Pharma are growing +18.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daewoong Pharma (069620) generate?
The free cash flow of Daewoong Pharma is −92.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daewoong Pharma (069620) carry?
The net debt of Daewoong Pharma is 658B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daewoong Pharma in the live analysis
One click puts Daewoong Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
